Education Posters Resources General Info Supporters

Registration Options

Activity Date: 04/19/2016

Target Audience

This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

The purpose of the Pipeline session is to present the very latest information about new CNS compounds to attendees at the CPNP Annual Meeting with the goal being that attendees will learn about the most promising agents in the specialty drug pipeline.

4:30-4:32: Session and Speaker Introduction
Jerry Overman, PharmD, BCPP

4:32-5:52 p.m.: Efficacy and Safety of LY2951742 in a Phase IIB, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
Authors: Stauffer VL1,Skljarevski V1, Zhang Q1, Ferguson MB1, Oakes TM1, Martinez JM1, Johnson KW1, Schacht AL1, Due MR1, Dodick DW2
1Eli Lilly and Company, Indianapolis, IN; 2Mayo Clinic, Phoenix, AZ

1Eli Lilly and Company, Indianapolis, IN; 2Mayo Clinic, Phoenix, AZ

Speaker: Virginia Stauffer, PharmD

4:52-4:53 p.m.: Speaker Introduction
Jerry Overman, PharmD, BCPP

4:53-5:13 p.m.: Efficacy and Safety of Intravenous Esketamine in Patients with Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Phase 2a Study
Authors: Jaskaran B. Singh, Maggie Fedgchin, Ella Daly, Liwen Xi, Caroline Melman, Geert De Bruecker, Andre Tadic, Pascal Sienaert, Frank Wiegand, Husseini Manji, Wayne C. Drevets, and Luc Van Nueten
Speaker: Dean Najarian, PharmD, BCPP

5:13-5:15 p.m.: Session Conclusion
Jerry Overman, PharmD, BCPP

Course Requirements

To receive ACPE credit for the live session at the Annual Meeting, you must:

  • Sign in (or create a FREE account).
  • Register for this course. (sign in first)
  • Attend and participate in the entire session and reflect upon its teachings.
  • Complete the evaluation at the end of the activity. (sign in first)
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (sign in first)

This course will be provided at the CPNP 2016 Annual Meeting, April 17-20, 2016. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at http://cpnp.org/mycpnp/transcript/acpe.

Faculty Information and Disclosures

Virginia Stauffer, PharmD
Dean Najarian, PharmD, BCPP

View biographical information and disclosures

Learning Objectives

Efficacy and Safety of Intravenous Esketamine in Patients with Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Phase 2a Study

  1. To understand a novel mechanism of action for rapid antidepressant effect.
  2. To evaluate the safety, efficacy and dose response of intravenous esketamine in treatment resistant depression (TRD).

Efficacy and Safety of LY2951742 in a Phase IIB, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study

  1. To understand the role of a humanized monoclonal antibody to calcitonin gene-related peptide in the prevention of episodic migraine headache.
  2. To understand dose selection of LY2957142 for Phase III development for the prevention of episodic migraine headache.

Continuing Education Credit and Disclosures

Activity Date: 04/19/2016
ACPE Contact Hours: 0.75
ACPE Number: 0284-0000-16-019-L01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 0.75 contact hours (0.075 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-16-019-L01-P (.75 contact hours).